Sun Pharma Reports Strong Q4 FY26 Results

Sun Pharmaceutical Industries announced a robust financial performance for the fourth quarter ended March 31, 2026. Consolidated sales climbed 13.6% year-on-year to Rs 145,598 million, while net profit saw a significant surge of 26.2%, reaching Rs 27,140 million.

For the full fiscal year FY26, the company achieved consolidated sales growth of 11.9%, totaling Rs 582,201 million. Net profit for the year increased by 5.0% to Rs 114,794 million.

Key Financial Highlights

Sun Pharma's Q4 performance was marked by strong top-line and bottom-line growth. The company reported a 13.6% year-on-year increase in Q4 sales, reaching Rs 145,598 million. Net profit for the same quarter jumped 26.2% to Rs 27,140 million. Over the full fiscal year FY26, consolidated sales grew by 11.9% to Rs 582,201 million, with net profit rising 5.0% to Rs 114,794 million.

Driving Factors for Growth

The company's strategic focus on expanding its specialty and innovative medicines portfolio, particularly in the U.S. market, is paying dividends. A significant milestone was the U.S. Innovative Medicines business crossing the $1 billion revenue mark. This, combined with strong performance in the Indian market, where Sun Pharma holds a leading position in formulations with a 14.8% growth in Q4 and 14% for the full year, underpinned the overall financial results.

Investor Confidence and Future Outlook

This solid financial performance is expected to bolster investor confidence in Sun Pharma's growth strategy. The company has recommended a final dividend of Rs 5.00 per share for FY26. While U.S. Formulations sales experienced a slight 1.1% decline in Q4, the growth in Innovative Medicines provided a strong offset. Investors will be closely watching for sustained momentum in the U.S. market and continued leadership in India, as well as progress in the company's R&D pipeline.